Tarlatamab for treating relapsed small cell lung cancer after platinum-based chemotherapy

Tarlatamab is in clinical development for the treatment of relapsed small cell lung cancer (SCLC) after platinum-based first-line chemotherapy. SCLC is a disease in which malignant (cancer) cells form in the tissues of the lung. SCLC is a particularly aggressive form of the disease and tends to spread faster than non-SCLC, with more than two third of people with SCLC having metastatic disease at the time of diagnosis. Metastasis is when cancer spreads from its original location to other areas of the body. Despite being both a chemo- and radiation-sensitive malignancy, SCLC recurrence occurs in most cases and negatively impacts patients’ prognosis. There is an unmet need for second line treatment options for relapsed SCLC.